Minireviews
Copyright ©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Exp Med. Aug 20, 2015; 5(3): 188-193
Published online Aug 20, 2015. doi: 10.5493/wjem.v5.i3.188
Multiplex planar microarrays for disease prognosis, diagnosis and theranosis
Peter Lea
Peter Lea, SQI Diagnostic Systems Inc., Toronto, Ontario M9W 1A4, Canada
Author contributions: Lea P solely contributed to this work.
Conflict-of-interest statement: None.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Peter Lea, PhD, SQI Diagnostic Systems Inc, 36 Meteor Drive, Toronto, Ontario M9W 1A4, Canada. plea@sqidiagnostics.com
Telephone: +1-416-6749500
Received: September 16, 2014
Peer-review started: September 16, 2014
First decision: October 28, 2014
Revised: June 5, 2015
Accepted: August 4, 2015
Article in press: August 7, 2015
Published online: August 20, 2015
Abstract

Advanced diagnostic methods and algorithms for immune disorders provide qualitative and quantitative multiplex measurement for pre-clinical prognostic and clinical diagnostic biomarkers specific for diseases. Choice of therapy is confirmed by modulating diagnostic efficacy of companion, theranotic drug concentrations. Assay methods identify, monitor and manage autoimmune diseases, or risk thereof, in subjects who have, or who are related to individuals with autoimmune disease. These same diagnostic protocols also integrate qualitative and quantitative assay test protocol designs for responder patient assessment, risk analysis and management of disease when integrating multiplex planar microarray diagnostic tests, patient theranostic companion diagnostic methods and test panels for simultaneous assessment and management of dysimmune and inflammatory disorders, autoimmunity, allergy and cancer. Proprietary assay methods are provided to identify, monitor and manage dysimmune conditions, or risk thereof, in subjects with pathological alterations in the immune system, or who are related to individuals with these conditions. The protocols can be used for confirmatory testing of subjects who exhibit symptoms of dysimmunity, as well as subjects who are apparently healthy and do not exhibit symptoms of altered immune function. The protocols also provide for methods of determining whether a subject has, is at risk for, or is a candidate for disease therapy, guided by companion diagnosis and immunosuppressive therapy, as well as therapeutic drug monitoring and theranostic testing of disease biomarkers in response to immuno-absorption therapy. The multiplex test panels provide the components that are integral for performing the methods to recognized clinical standards.

Keywords: Simultaneous methods, Multiplex planar microarrays, Disease integrated panels, Theranosis, Prognosis, Diagnosis

Core tip: Multiplex planar microarrays integrated for simultaneous, quantitative methods of prognosis, diagnosis, and theranosis provide a powerful technology for comparative measurements of changes in disease states and risk analysis, especially for autoimmune diseases.